Comparative Pharmacology
Head-to-head clinical analysis: DEPO PROVERA versus KIRSTY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO PROVERA versus KIRSTY.
DEPO-PROVERA vs KIRSTY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibiting ovulation and causing endometrial thinning.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the central nervous system, potentiating serotonergic activity.
150 mg intramuscularly every 3 months (13 weeks) for contraception; for endometriosis, 50 mg subcutaneously once weekly or 150 mg intramuscularly every 90 days.
Not established; no approved dosing available.
None Documented
None Documented
Terminal elimination half-life is approximately 12-17 hours after single dose, but after multiple doses or depot administration, the half-life extends to about 40-60 hours due to slow release from injection site.
12.4 ± 3.1 hours in healthy adults; prolonged in hepatic impairment (24–36 hours) and in elderly (15–20 hours).
Primarily metabolized in the liver via hydroxylation and conjugation; metabolites are excreted in urine (60-70%) and feces (20-30%). Less than 1% excreted unchanged in urine.
Primarily hepatic metabolism to inactive metabolites; 5% excreted renally unchanged; 95% eliminated in feces via biliary secretion.
Category C
Category C
Progestin-Only Contraceptive
Progestin-Only Contraceptive